Avandia gets suspended in the EU and severely restricted in the US
This article was originally published in SRA
Executive Summary
The European Medicines Agency has suspended the marketing authorisation for all rosiglitazone-containing products, following months of review of data on GlaxoSmithKline's Avandia and its link to cardiovascular safety issues 1. The US Food and Drug Administration, meanwhile, has decided not remove Avandia from the market but will impose severe new restrictions on its use2.